Disrupting the Rb-Raf-1 interaction: A potential therapeutic target for cancer

Drug News and Perspectives

Volumn 21, Issue 6, 2008, Pages 331-335

  Davis, Rebecca K ^a   Chellappan, Srikumar ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CY 202; CYCLIN DEPENDENT KINASE; FLAVOPIRIDOL; GLUTATHIONE TRANSFERASE; L 779450; NSC 35400; NSC 35950; PEPTIDE; PROTEIN BCL X; RAF PROTEIN; RETINOBLASTOMA PROTEIN; RRD 251; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; IN VIVO STUDY; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-RAF; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION;

EID: 56249094537     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.6.1246832     Document Type: Review

References (31)

1. Knudsen, E.S. and Knudsen, K.E. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) 2006, 231(7): 1271-81.
2. Wang, S., Ghosh, R.N. and Chellappan, S.P. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 1998, 18(12): 7487-98.
3. Dasgupta, P., Rastogi, S., Pillai, S., Ordonez-Ercan, D., Morris, M., Haura, E. and Chellappan S. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006, 116(8): 2208-2217.
4. Bartkova, J., Lukas, J., Strauss, M. and Bartek, J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995, 10(4): 775-8.
5. Bellacosa, A., Almadori, G., Cavallo, S. et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996, 2(1): 175-80.
6. Gillett, C., Fantl, V., Smith, R. et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994, 54(7): 1812-7.
7. Sheyn, I., Noffsinger, A.E., Heffelfinger, S., Davis, B., Miller, M.A. and Fenoglio-Preiser, C.M. Amplification and expression of the cyclin D1 gene in anal and esophageal squamous cell carcinomas. Hum Pathol 1997, 28(3): 270-6.
8. Yatabe, Y., Nakamura, S., Seto, M. et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol 1996, 20(9): 1110-22.
9. Geradts, J., Kratzke, R.A., Niehans, G.A. and Lincoln, C.E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p161NK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995, 55 (24): 6006-11.
10. Kratzke, R.A., Greatens, T.M., Rubins, J.B., Maddaus, M.A., Niewoehner, D.E., Niehans, G.A. and Geradts, J. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996, 56(15): 3415-20.
11. Ottetson, G.A., Kratzke, R.A., Coxon, A., Kim, Y.W. and Kaye, F.J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994, 9(11): 3375-8.
12. Sakaguchi, M., Fujii, Y., Hirabayashi, H. et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996, 65(4): 442-5.
13. Shapiro, G.I., Edwards, C.D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D.J. and Rollins, B.J. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995, 55(3): 505-9.
14. Dyson, N., Howley, P.M., Münger, K. and Harlow, E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243(4893): 934-7.
15. Münger, K., Werness, B.A., Dyson, N., Phelps, W.C., Harlow, E. and Howley, P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989, 8(13): 4099-105.
16. Kitagawa, M., Taya, Y. [Cell-cycle regulation via phosphorylation of RB protein by cyclin-dependent kinase]. Tanpakushitsu Kakusan Koso 1997, 42(10 Suppl): 1594-602.
17. Taya Y. RB kinases and RB-binding proteins: new points of view. Trends Biochem Sci 1997, 22(1): 14-7.
18. D'Abaco, G.M., Hooper, S., Paterson, H. and Marshall, C.J. Loss of Rb overrides the requirement for ERK activity for cell proliferation. J Cell Sci 2002, 115(Pt 23): 4607-16.
19. Garnovskaya, M.N., Mukhin, Y.V., Vlasova, T.M., Grewal, J.S., Ullian, M.E., Tholanikunnel, B.G. and Raymond, J.R. Mitogen-induced rapid phosphorylation of serine 795 of the retinoblastoma gene product in vascular smooth muscle cells involves ERK activation. J Biol Chem 2004, 279(23): 24899-905.
20. Downward J. Cell cycle: routine role for Ras. Curr Biol 1997, 7(4): R258-60.
21. Dasgupta, P., Sun, J., Wang, S. et al. Disruption of the Rb-Raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 2004, 24(21): 9527-41.
22. Hood, J.D. and Cheresh, D.A. Targeted delivery of mutant Raf kincise to neovessels causes tumor regression. Cold Spring Harb Symp Quant Biol 2002, 67: 285-91.
23. Kinkade, R., Dasgupta, P. and Chellappan, S. The ABCs of targeting Raf: Novel approaches to cancer therapy. Curr Cancer Ther Rev 2006, 2(4): 305-14.
24. Wilhelm, S., Carter, C., Lynch, M. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 5(10): 835-44.
25. Wilhelm, S.M., Carter, C., Tang, L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19): 7099-109.
26. Heimbrook, D.C. and Oliff, A. Therapeutic intervention and signaling. Curr Opin Cell Biol 1998, 10(2): 284-8.
27. de Cárcer, G., de Castro, I.P. and Malumbres, M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007, 14(9): 969-85.
28. Malumbres, M., Pevarello, P., Barbacid, M. and Bischoff, J.R. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008, 29(1): 16-21.
29. Berthet, C., Aleem, E., Coppola, V., Tessarollo, L. and Kaldis, P. Cdk2 knockout mice are viable. Curr Biol 2003, 13(20): 1775-85.
30. Malumbres, M., Sotillo, R., Santamaría, D. et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004, 118(4): 493-504.
31. Kinkade, R., Dasgupta, P., Carie, A. et al. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Res 2008, 68(10): 3810-8.